We are live on
!
Find out more
AVM
Arch Venture Management Portfolio holdings
AUM
$677M
1-Year Est. Return
322.07%
This Fund
S&P 500
This Quarter
Est. Return
+46.75%
1 Year Est. Return
+322.07%
3 Year Est. Return
+208.96%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$771M
AUM Growth
-$49.3M
(-6%)
Cap. Flow
-$382M
Cap. Flow
% of AUM
-49.57%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
1
Increased
–
Reduced
3
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UBX
Unity Biotechnology
UBX
|
+$6.34M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$324M |
| 2 |
Denali Therapeutics
DNLI
|
+$48.8M |
| 3 |
VERV
Verve Therapeutics
VERV
|
+$16M |
| 4 |
ZY
Zymergen Inc. Common Stock
ZY
|
+$147K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.27% |
| 2 | Financials | 1.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $295M | 38.28% |
1,312,872
-1,600,000
| -55% | -$324M |
|
|
EQRX
2
DELISTED
EQRx, Inc. Common Stock
EQRX
| $180M | 23.32% |
36,335,375
| – | – |
|
|
3
Denali Therapeutics
DNLI
$3.7B
| $113M | 14.6% |
3,668,749
-1,500,000
| -29% | -$48.8M |
|
4
Erasca
ERAS
$6.66B
| $86.2M | 11.18% |
11,055,554
| – | – |
|
|
VERV
5
DELISTED
Verve Therapeutics
VERV
| $69M | 8.95% |
2,008,809
-500,000
| -20% | -$16M |
|
|
REVH
6
DELISTED
Revolution Healthcare Acquisition Corp. SAIL Class A Common Stock
REVH
| $13.3M | 1.73% |
1,357,237
| – | – |
|
|
OMIC
7
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $9.5M | 1.23% |
126,631
| – | – |
|
|
UBX
8
DELISTED
Unity Biotechnology
UBX
| $3.97M | 0.51% |
+1,004,818
| New | +$6.34M |
|
|
MTCR
9
DELISTED
Metacrine, Inc. Common Stock
MTCR
| $1.43M | 0.18% |
2,940,503
| – | – |
|
|
RUBY
10
DELISTED
Rubius Therapeutics, Inc
RUBY
| $152K | 0.02% |
349,908
| – | – |
|
|
ZY
11
DELISTED
Zymergen Inc. Common Stock
ZY
| – | – |
-119,205
| Closed | -$147K |
|
Similar funds
NI
MMPW
JC
NCM
TWM
DLIC
REAM
MCO
Arch Venture Management's Q3 2022 Portfolio in Review
As of Q3 2022, Arch Venture Management held 11 positions worth $771M, down 6% from $821M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Arch Venture Management withdrew a net $382M in Q3 2022, closing 1 position and reducing 3 holdings. Its most notable exit was Zymergen Inc. Common Stock, an estimated $147K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Financials.
Against the trend, Arch Venture Management opened a new position in Unity Biotechnology worth $3.97M.
- Arch Venture Management's largest Q3 2022 buy was Unity Biotechnology: 1,004,818 shares worth $3.97M.
- Arch Venture Management's biggest Q3 2022 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $324M.
- Arch Venture Management fully exited Zymergen Inc. Common Stock in Q3 2022, selling an estimated $147K.
- Arch Venture Management's ten largest holdings make up 100% of its $771M portfolio in Q3 2022.
- Arch Venture Management opened 1 new position and closed 1 in Q3 2022.
- Arch Venture Management's portfolio value fell 6% quarter-over-quarter to $771M.
Based on Arch Venture Management's 13F filing for Q3 2022, filed 10 Nov 2022.